• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Q32 Bio Inc.

    7/6/26 7:20:16 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QTTB alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Q32 Bio Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)




    746964105

    (CUSIP Number)
    06/30/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    746964105


    1Names of Reporting Persons

    The Carlyle Group Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    691,735.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    691,735.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    691,735.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.1 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP Number(s):
    746964105


    1Names of Reporting Persons

    Carlyle Holdings I GP Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    691,735.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    691,735.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    691,735.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.1 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP Number(s):
    746964105


    1Names of Reporting Persons

    Carlyle Holdings I GP Sub L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    691,735.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    691,735.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    691,735.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.1 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Limited Liability Company


    SCHEDULE 13G

    CUSIP Number(s):
    746964105


    1Names of Reporting Persons

    Carlyle Holdings I L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    691,735.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    691,735.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    691,735.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.1 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    746964105


    1Names of Reporting Persons

    CG Subsidiary Holdings L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    691,735.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    691,735.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    691,735.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.1 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Limited Liability Company


    SCHEDULE 13G

    CUSIP Number(s):
    746964105


    1Names of Reporting Persons

    TC Group, L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    691,735.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    691,735.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    691,735.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.1 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Limited Liability Company


    SCHEDULE 13G

    CUSIP Number(s):
    746964105


    1Names of Reporting Persons

    Carlyle Investment Management L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    691,735.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    691,735.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    691,735.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.1 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Limited Liability Company


    SCHEDULE 13G

    CUSIP Number(s):
    746964105


    1Names of Reporting Persons

    Carlyle Genesis UK LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    691,735.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    691,735.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    691,735.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.1 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Limited Liability Company


    SCHEDULE 13G

    CUSIP Number(s):
    746964105


    1Names of Reporting Persons

    Abingworth LLP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    691,735.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    691,735.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    691,735.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.1 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    746964105


    1Names of Reporting Persons

    Abingworth Bioventures VII LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    691,735.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    691,735.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    691,735.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.1 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Q32 Bio Inc.
    (b)Address of issuer's principal executive offices:

    830 Winter Street, Waltham, MA, 02451
    Item 2. 
    (a)Name of person filing:

    Each of the following is hereinafter individually referred to as a "Reporting Person" and collectively as the "Reporting Persons." This statement is filed on behalf of: The Carlyle Group Inc. Carlyle Holdings I GP Inc. Carlyle Holdings I GP Sub L.L.C. Carlyle Holdings I L.P. CG Subsidiary Holdings L.L.C. TC Group, L.L.C. Carlyle Investment Management L.L.C. Carlyle Genesis UK LLC Abingworth LLP Abingworth Bioventures VII LP
    (b)Address or principal business office or, if none, residence:

    The principal business address of each of Abingworth LLP and Abingworth Bioventures VII LP is 38 Jermyn Street, London, SW1Y 6DN, England, United Kingdom. The principal business address of each of the other Reporting Persons is c/o The Carlyle Group, 1001 Pennsylvania Ave. NW, Suite 220 South, Washington, DC 20004-2505.
    (c)Citizenship:

    Each of Abingworth LLP and Abingworth Bioventures VII LP is organized under the laws of England and Wales. Each of the other Reporting Persons is organized under the laws of the State of Delaware.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    746964105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information contained on the cover pages to this Schedule 13G is incorporated by reference into this Item 4. The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of June 18, 2026, based upon 16,956,415 shares of Common Stock outstanding, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 5, 2026. Abingworth Bioventures VII LP is the record holder of the shares of Common Stock reported herein. The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Abingworth Bioventures VII LP has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by them. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by Abingworth Bioventures VII LP, but each disclaims beneficial ownership of such securities.
    (b)Percent of class:

    4.1%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    691,735

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    691,735

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Carlyle Group Inc.
     
    Signature:/s/ Anne K. Frederick
    Name/Title:Anne K. Frederick, Corporate Secretary
    Date:07/06/2026
     
    Carlyle Holdings I GP Inc.
     
    Signature:/s/ Anne K. Frederick
    Name/Title:Anne K. Frederick, Managing Director
    Date:07/06/2026
     
    Carlyle Holdings I GP Sub L.L.C.
     
    Signature:By: Carlyle Holdings I GP Inc., its sole member, /s/ Anne K. Frederick
    Name/Title:Anne K. Frederick, Managing Director
    Date:07/06/2026
     
    Carlyle Holdings I L.P.
     
    Signature:/s/ Anne K. Frederick
    Name/Title:Anne K. Frederick, Managing Director
    Date:07/06/2026
     
    CG Subsidiary Holdings L.L.C.
     
    Signature:/s/ Anne K. Frederick
    Name/Title:Anne K. Frederick, Managing Director
    Date:07/06/2026
     
    TC Group, L.L.C.
     
    Signature:/s/ Anne K. Frederick
    Name/Title:Anne K. Frederick, Managing Director
    Date:07/06/2026
     
    Carlyle Investment Management L.L.C.
     
    Signature:/s/ Anne K. Frederick
    Name/Title:Anne K. Frederick, Managing Director
    Date:07/06/2026
     
    Carlyle Genesis UK LLC
     
    Signature:By: Carlyle Investment Management L.L.C., its sole member, /s/ Anne K. Frederick
    Name/Title:Anne K. Frederick, Managing Director
    Date:07/06/2026
     
    Abingworth LLP
     
    Signature:/s/ Emma O'Reilly
    Name/Title:Emma O'Reilly. Authorized Signatory
    Date:07/06/2026
     
    Abingworth Bioventures VII LP
     
    Signature:/s/ Emma O'Reilly
    Name/Title:Emma O'Reilly. Authorized Signatory
    Date:07/06/2026
    Exhibit Information

    Exhibit 99: Joint Filing Agreement (previously filed)

    Get the next $QTTB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QTTB

    DatePrice TargetRatingAnalyst
    5/18/2026Overweight
    Cantor Fitzgerald
    2/25/2026$13.00Buy
    H.C. Wainwright
    2/11/2025$22.00 → $3.00Outperform → Market Perform
    BMO Capital Markets
    2/11/2025$20.00 → $4.00Overweight → Neutral
    Piper Sandler
    12/11/2024Buy → Neutral
    Guggenheim
    12/11/2024$95.00 → $16.00Overweight → Equal Weight
    Wells Fargo
    12/11/2024$90.00 → $22.00Strong Buy → Outperform
    Raymond James
    12/11/2024$68.00 → $9.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $QTTB
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Q32 Bio Inc.

    SCHEDULE 13D/A - Q32 Bio Inc. (0001661998) (Subject)

    7/20/26 9:32:47 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Q32 Bio Inc.

    S-3 - Q32 Bio Inc. (0001661998) (Filer)

    7/17/26 4:14:39 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Q32 Bio Inc.

    8-K - Q32 Bio Inc. (0001661998) (Filer)

    7/15/26 5:18:59 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Xu Diyong bought $15,000,000 worth of shares (1,875,000 units at $8.00) (SEC Form 4)

    4 - Q32 Bio Inc. (0001661998) (Issuer)

    6/1/26 9:15:32 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orbimed Advisors Llc bought $15,000,000 worth of shares (1,875,000 units at $8.00) (SEC Form 4)

    4 - Q32 Bio Inc. (0001661998) (Issuer)

    6/1/26 9:13:02 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants

    WALTHAM, Mass., July 14, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the pricing of an underwritten public offering of 6,027,399 shares of its common stock at a public offering price of $18.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 4,931,506 shares of its common stock at a public offering price of $18.2499 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-fu

    7/14/26 10:58:00 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

    WALTHAM, Mass., July 13, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that it has commenced an underwritten public offering of $200 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Q32 Bio intends to grant the underwriters a 30-day option to purchase up to an additional $30 million of shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissio

    7/13/26 4:01:00 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata

    -- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline of 35.3% in the prespecified mITT analysis ---- 40.0% of patients achieved SALT-20 response at Week 36 in the mITT analysis and 30.3% of patients achieved SALT-20 response at Week 36 in the ITT analysis of all enrolled patients ---- Generally well-tolerated safety profile, consistent with prior studies, with no new safety signals ---- Bempikibart demonstrated a favorable PK, PD and ADA profile -- -- Data supports further development of bempikibart in alopecia areata; Company intends to advance a registration-directed program in the first half of 2027 ---- Q32

    7/13/26 6:59:00 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Violette Shelia M. was granted 37,500 shares, increasing direct ownership by 40% to 130,569 units (SEC Form 4)

    4 - Q32 Bio Inc. (0001661998) (Issuer)

    7/20/26 9:31:18 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Morrison Jodie Pope was granted 132,000 shares, increasing direct ownership by 60% to 353,104 units (SEC Form 4)

    4 - Q32 Bio Inc. (0001661998) (Issuer)

    7/20/26 9:27:42 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO and President Kalowski Lee was granted 53,250 shares, increasing direct ownership by 60% to 142,443 units (SEC Form 4)

    4 - Q32 Bio Inc. (0001661998) (Issuer)

    7/20/26 9:25:35 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Q32 Bio

    Cantor Fitzgerald initiated coverage of Q32 Bio with a rating of Overweight

    5/18/26 8:36:12 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Q32 Bio with a new price target

    H.C. Wainwright initiated coverage of Q32 Bio with a rating of Buy and set a new price target of $13.00

    2/25/26 7:53:48 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio downgraded by BMO Capital Markets with a new price target

    BMO Capital Markets downgraded Q32 Bio from Outperform to Market Perform and set a new price target of $3.00 from $22.00 previously

    2/11/25 7:55:03 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Q32 Bio Inc.

    SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)

    11/14/24 5:46:10 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Q32 Bio Inc.

    SC 13G - Q32 Bio Inc. (0001661998) (Subject)

    11/13/24 4:05:13 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Q32 Bio Inc.

    SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)

    10/25/24 6:06:25 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QTTB
    Financials

    Live finance-specific insights

    View All

    Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata

    -- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline of 35.3% in the prespecified mITT analysis ---- 40.0% of patients achieved SALT-20 response at Week 36 in the mITT analysis and 30.3% of patients achieved SALT-20 response at Week 36 in the ITT analysis of all enrolled patients ---- Generally well-tolerated safety profile, consistent with prior studies, with no new safety signals ---- Bempikibart demonstrated a favorable PK, PD and ADA profile -- -- Data supports further development of bempikibart in alopecia areata; Company intends to advance a registration-directed program in the first half of 2027 ---- Q32

    7/13/26 6:59:00 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026

    -- Conference call to be held Monday, July 13th at 8:00 a.m. E.T. --WALTHAM, Mass., July 10, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced it will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA on Monday, July 13, 2026. Following the announcement, Q32 Bio will host a conference call and webcast at 8:00 a.m. E.T. on Monday, July 13, 2026 to discuss the results.Conference CallQ32 Bio's live conference call an

    7/10/26 4:05:00 PM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference

    WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 12:45 p.m. E.T. on Wednesday, April 15, 2026 at the 25th Annual Needham Virtual Healthcare Conference.A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. An archived replay will be available for 90 days following the event.About Q32 BioQ32 Bio is a clinical stage biotechnology company whose science targets potent

    4/8/26 6:59:00 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care